The Coalition for Epidemic Preparedness Innovations (CEPI) and Gennova Biopharmaceuticals Ltd, based in Pune, have unveiled a new funding agreement aimed at advancing their self-amplifying mRNA (saRNA) platform. This collaborative effort intends to develop vaccine candidates against potential unknown pathogenic threats, commonly referred to as Disease X.
In accordance with the statement released, CEPI is set to contribute up to $3.6 million to support the enhancement of the saRNA-platform technology, refining the production process and increasing yield. The initial objective will involve creating a vaccine candidate targeting the rabies virus, which belongs to the Rhabdoviridae virus family. This candidate will undergo preclinical studies, utilizing the rabies virus as a known benchmark with established measures of protection. This will aid in evaluating the efficacy of this novel technology.
CEPI’s initiative to bolster novel RNA vaccine platform technologies for emerging infectious diseases and select endemic conditions is rooted in the potential advantages they offer over existing mRNA technologies. These advantages encompass areas such as multivalency, enhanced immunogenicity, improved storage stability, higher productivity, quicker response time, and lower cost-of-goods.
The statement highlights that Gennova’ssaRNA vaccine platform could be an integral part of CEPI’s efforts to enable swift and equitable access to technology for future epidemic and pandemic responses, potentially within 100 days of identifying a threat.
Through this collaboration with CEPI, Gennova underscores its commitment to ensuring fair access to its technology in alignment with CEPI’s Equitable Access Policy. The company emphasizes its dedication to prioritizing at-risk populations with affordable vaccines that are available where and when needed.
Dr. Melanie Saville, Executive Director of Vaccine R&D, emphasizes the critical role of RNA vaccine technology in global responses to outbreaks and underlines CEPI’s focus on supporting advanced RNA vaccine technologies that offer scalability, thermostability, immunogenicity, and affordability—qualities that make them versatile platforms for rapid response against emerging infectious threats.
Gennova’s track record of collaborations with esteemed research institutes worldwide, coupled with its experience in infectious diseases and vaccinology, positions the company well for pandemic-ready manufacturing using the mRNA-based platform. The collaboration with CEPI aims to further enhance this technology for wider vaccine access and global equity.
Dr. Sanjay Singh, Chief Executive Officer of Gennova, expresses enthusiasm for the partnership with CEPI, highlighting the successful development of mRNA-based COVID-19 vaccines by Gennova during the pandemic. He underscores the shared goal of advancing the saRNA-technology platform for more equitable vaccine distribution and access.